Vytorin Articles
Vytorin beats Lipitor in high-risk patients
21 March 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Merck & Co's first taste of life after Vioxx; earnings per share to take substantial hit
20 December 2004
Statins to open door for more US OTC switches?
20 September 2004
Disappointing new data for Merck & Co's Zocor in patients with ACS
6 September 2004
Stock Commentary - New York
2 August 2004
Merck & Co/S-P's Vytorin OKed by FDA
2 August 2004
Schering-Plough sees 2nd-qtr losses
26 July 2004
Stock Commentary - New York
19 July 2004
Stock Commentary - New York
12 July 2004
Stock Commentary - New York
5 July 2004
NZ to fund Merck & Co/ S-P cholesterol drugs
21 June 2004
S-P's Hassan outlines vision for future
3 May 2004
Merck & Co/S-P's Inegy OKed in Germany
12 April 2004
Stock Commentary - New York
2 February 2004
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
